(NASDAQ: MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today provided an ...

Researchers have uncovered a stealth survival strategy that melanoma cells use to evade targeted therapy, offering a ...

Researchers have uncovered a promising therapeutic target for adenoid cystic carcinoma (ACC), a rare cancer of the salivary ...

The data from the Phase 1/1b clinical trial of soquelitinib in patients with T cell lymphoma continues to demonstrate strong indications of anti-tumor activity in a significant number of patients,” ...

Reports Q4 revenue $60.6M, consensus $51.9M. “We continue to make excellent progress with our clinical and preclinical molecular glue degrader ...

Targeted inhibition of a "signal jammer" protein may improve how tumors respond to immunotherapy. Published today in Nature, a new study demonstrates how some cancer cells use the protein ...

St. Jude researchers identified a protein, voltage-dependent anion channel 2 (VDAC2), that tumors use as a “signal jammer” to prevent cancer cell death and evade the immune system’s functioning.

Up to 25% of new mothers suffer from postpartum depression, which can significantly impact their parenting behavior and the wellbeing of their children. A new study looks at long-term effects of early ...

Maternal postpartum depression at six weeks is linked to reduced inhibition and emotional control in children alongside ...

Glioblastoma has long resisted treatment, but scientists may have found a breakthrough by leveraging the body's own ...